Renal Cell Carcinoma News

RCC: Computer-assisted Tumor Response Reduces Evaluation Errors

RCC: Computer-assisted Tumor Response Reduces Evaluation Errors

Computer-assisted evaluation of tumor response reduced errors and time of evaluation compared with standard-of-care.

Cryoablation May Offer Oncologic Control in cT1 Solitary Renal Masses

Cryoablation May Offer Oncologic Control in cT1 Solitary Renal Masses

Cryoablation was associated with good short-term oncologic control and an excellent safety profile in "healthier" patients.

Genetic Conditions and Renal Cell Carcinoma

Genetic Conditions and Renal Cell Carcinoma

The understanding of genetic conditions with predisposition to renal cell cancer is critical for developing better therapies.

Safety of Active Surveillance for Small Renal Masses

Safety of Active Surveillance for Small Renal Masses

Active surveillance appears to be a safe alternative to primary intervention for selected patients with small renal masses.

Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC

Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC

Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy.

Genomic Alterations in Metastatic Renal Cell Carcinoma

Genomic Alterations in Metastatic Renal Cell Carcinoma

Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.

Impact of Early Immunotherapy Discontinuation in mRCC

Impact of Early Immunotherapy Discontinuation in mRCC

Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early may still achieve durable responses.

ABX May Affect Efficacy of Checkpoint Inhibitors in RCC

ABX May Affect Efficacy of Checkpoint Inhibitors in RCC

Patients with advanced kidney cancer received broad-spectrum antibiotics less than a month before initiating immune checkpoint inhibitor therapy.

Fumarate Hydratase Mutations and Renal Tumors: When Is Genetic Testing Appropriate?

Fumarate Hydratase Mutations and Renal Tumors: When Is Genetic Testing Appropriate?

Patients with kidney tumors with pathology indicating a fumarate hydratase (FH) mutation should be referred for genetic testing.

ASCO Releases Guideline for the Management of Small Renal Masses

ASCO Releases Guideline for the Management of Small Renal Masses

ASCO published new recommendations for the management of patients with clinically localized small renal masses (SRMs).

Dalantercept and Axitinib in Renal Cell Carcinoma

Dalantercept and Axitinib in Renal Cell Carcinoma

Combining dalantercept with axitinib treatment may improve clinical outcomes for previously treated patients with renal cell carcinoma (RCC).

Adjuvant Chemo After RNU May Improve Survival in Urothelial Carcinoma

Adjuvant Chemo After RNU May Improve Survival in Urothelial Carcinoma

Adjuvant chemotherapy after radical nephroureterectomy (RNU) may improve overall survival compared with observation alone.

MK-2206 Not Superior to Everolimus for Renal Cell Carcinoma

MK-2206 Not Superior to Everolimus for Renal Cell Carcinoma

Allosteric inhibition of AKT with MK-2206 is not superior to everolimus for the treatment of patients with advanced renal cell carcinoma (RCC).

Cabozantinib Superior to Sunitinib for First-line Treatment of mRCC

Cabozantinib Superior to Sunitinib for First-line Treatment of mRCC

Among patients with intermediate- or poor-risk metastatic renal cell carcinoma (mRCC), first-line therapy with cabozantinib was superior to standard-of-care.

Nephrectomy After Pazopanib Feasible for Metastatic ccRCC

Nephrectomy After Pazopanib Feasible for Metastatic ccRCC

Among patients with intermediate-risk metastatic clear cell renal cell carcinoma (ccRCC), nephrectomy after upfront pazopanib therapy is feasible.

Sonepcizumab With VEGF Inhibitors Improves Overall Survival in mRCC

Sonepcizumab With VEGF Inhibitors Improves Overall Survival in mRCC

Sonepcizumab improves overall survival of patients with metastatic renal cell carcinoma (mRCC).

Adjuvant Sunitinib Prolongs DFS in High-risk Locoregional Renal Cell Carcinoma

Adjuvant Sunitinib Prolongs DFS in High-risk Locoregional Renal Cell Carcinoma

Adjuvant treatment with sunitinib prolonged disease-free survival, and was associated with a manageable safety profile.

No Significant Overall Survival Benefit With Sunitinib Plus IMA901 in RCC

No Significant Overall Survival Benefit With Sunitinib Plus IMA901 in RCC

The vaccine IMA901 did not improve overall survival when added to sunitinib as a first-line treatment for patients with metastatic renal cell carcinoma (RCC).

Final Analysis Demonstrates Some Benefit With Everolimus in Papillary mRCC

Final Analysis Demonstrates Some Benefit With Everolimus in Papillary mRCC

First-line single-agent everolimus provides some clinical benefit to patients with papillary metastatic renal cell carcinoma (mRCC).

FDA Modifies Nivolumab Dosage Regimens for RCC, NSCLC, Melanoma

FDA Modifies Nivolumab Dosage Regimens for RCC, NSCLC, Melanoma

The U.S. Food and Drug Administration (FDA) has modified the dosage regimen for nivolumab for the approved indications.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters